User:Mr. Ibrahem/Deferasirox

Deferasirox, sold under the brand name Exjade among others, is a medication used for chronic iron overload in those receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is generally only when deferoxamine is not sufficient. It is taken by mouth.

Common side effects include kidney problems, nausea, diarrhea, heart burn, rash, itchiness, and liver problems. Other side effects may include metabolic acidosis, bone marrow suppression, and gastrointestinal bleeding. It should not be used in people with kidney problems. It is believed to be harmful in pregnancy. It is an iron chelator.

Deferasirox was approved for medical use in the United States in 2005 and Europe in 2006. It is on the World Health Organization's List of Essential Medicines. In the United Kingdom a month at a dose of 360 mg per day costs the NHS about £500 as of 2021. In the United States this amount costs about 190 USD. Generic versions were approved in 2020.